The 46 references in paper O. Shakhmatova O., О. Шахматова О. (2016) “СПЕЦИФИЧЕСКИЕ АНТИДОТЫ К НОВЫМ ПЕРОРАЛЬНЫМ АНТИКОАГУЛЯНТАМ // SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS” / spz:neicon:aterotromboz:y:2016:i:1:p:81-94

1
Weitz JI. Anticoagulation therapy in 2015: where we are and where we are going. J Thromb Thrombolysis,
(check this in PDF content)
2
15, 39: 264-272. 2. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the ef_cacy and safety of new oral anticoagulants with warfarin in patients with atrial _brillation: a meta-analysis of randomised tri- als. Lancet,2014, 383: 955-962.
(check this in PDF content)
3
Majeed A, Hwang HG, Connolly SJ et al. Management and outcomes of major bleeding dur- ing treatment with dabigatran or warfarin. Circulation,2013, 128: 2325-2332.
(check this in PDF content)
4
Piccini JP, Garg J, Patel MR et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J, 2014, 35: 1873-1880.
(check this in PDF content)
5
Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol,2012, 87: S141-S145.
(check this in PDF content)
6
Miesbach W, Seifried E. New direct oral anticoagulants- current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost,2012, 108: 625-632.
(check this in PDF content)
7
Masotti L, Lorenzini G, Seravalle C et al. Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis, 2015, 39(4): 427-433.
(check this in PDF content)
8
Beyer-Westendorf J, Ebertz F, FЪrster K et al. Effectiveness and safety of dabiga- tran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost,2015, 113(6): 1247-1257.
(check this in PDF content)
9
Beyer-Westendorf J, FЪrster K, Pannach S et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 2014, 124(6): 955-962.
(check this in PDF content)
10
Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Eng J Med, 2011, 365: 2002-2012.
(check this in PDF content)
11
Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014, 383(9921): 955-962.
(check this in PDF content)
12
Hulle T, Kooiman J, Den Exter PL et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost, 2014, 12(3): 320-328.
(check this in PDF content)
13
Glund S, Stangier J, Schmohl M et al. Safety, tolerability, and ef_cacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, doubleblind phase 1 trial. Lancet,2015, 386: 680-690.
(check this in PDF content)
14
Schiele F, van Ryn J, Canada K et al. A speci_c antidote for dabigatran: functional and structural characterization. Blood, 2014, 121(18): 3554-3562.
(check this in PDF content)
15
Becker RC. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J Thromb Thrombolysis, 2016, 41: 273-278.
(check this in PDF content)
16
Honickel M, Treutler S, van Ryn J et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. J Thromb Haemost, 2015, 113(4): 671909.
(check this in PDF content)
17
Grottke O, Zentai C, van Ryn J et al. Binding of dabigatran to its specific antidote, idarucizumab, is not influenced by infusion solutions used during resuscitation in a porcine hemorrhagic shock model: 6AP3_6 (абстракт). Eur J Anaesthesiology, 2014, 31: 97.
(check this in PDF content)
18
Glund S, Moschetti V, Norris S et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost, 2015, 113: 943-951.
(check this in PDF content)
19
Glund S, Stangier J, Schmohl M et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood,
(check this in PDF content)
20
4, 124: 344 (abstract). 20.Pollack CV Jr, Reilly PA, Bernstein R et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a speci_c reversal agent for dabigatran. Thromb Haemost, 2015, 114: 198-205.
(check this in PDF content)
21
Pollack CV Jr, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med, 2015, 373: 511-520.
(check this in PDF content)
22
Frontera JA, Lewin III JJ, Rabinstein AA et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care,2016, 24(1): 6-46.
(check this in PDF content)
23
Lu G, DeGuzman FR, Hollenbach SJ et al. A speci_c antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 2013, 19: 446-451.
(check this in PDF content)
24
Lu G, DeGuzman FR, Hollenbach SJ et al. Reversal of low molecular weight heparin and fondaparinux by a recombinant antidote (r-antidote, PRT064445). Circulation, 2010, 122: A12420.
(check this in PDF content)
25
Слайды к докладу Mark Crowther на научной сессии Американского общества сердца 2014 г. ANNEXA™-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. http:// my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/@scon/documents/downloadable/ucm_469639.pdf.
(check this in PDF content)
26
Crowther M, Crowther MA. Antidotes for novel oral anticoagu- lants: current status and future potential. Arterioscler Thromb Vasc Biol, 2015, 35: 1736-1745.
(check this in PDF content)
27
Shah N, Rattu MA. Reversal agents for anticoagulants: focus on andexanet alfa. Am Student Res J, 2014, 1: 16-
(check this in PDF content)
28
28.Hollenbach S, Lu G, Deguzman F et al. Bolus administration of PRT064445, a recombinant factor Xa inhibitor antidote, reverses blood loss and PD markers in a rat model following enoxaparin-induced anticoagulation. Presented at the European Society of Cardiology Congress, Munich, Germany, August 25-29, 2012.
(check this in PDF content)
29
Lu G, DeGuzman F, Lakhotia S et al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. Blood, 2008, 112: 983.
(check this in PDF content)
30
Pine P, Hollenbach S, Tan S et al. Andexanet alfa reverses edoxaban-induced anticoagulation in a rabbit liver laceration model of acute bleeding. Presented at the European Society of Cardiology Congress, London, August 29—September 2, 2015.
(check this in PDF content)
31
Hollenbach S, Lu G, Tan S et al. PRT064445 but not rfVIIa or PCC reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model. Presented at the 54th annual meeting of the American Society of Hematology, Atlanta, December 8—11, 2012.
(check this in PDF content)
32
Crowther MA, Kitt M, McClure M et al. Randomized, double- blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for faxtor Xa inhibitors (abstract). Arterioscler Thromb Vasc Biol, 2013, 33: A10.
(check this in PDF content)
33
Crowther M, Lu G, Conley PB et al. Reversal of factor Xa inhibitors-induced anticoagulation in healthy subjects by andexanet alfa. Crit Care Med,2014, 42(12): A1469.
(check this in PDF content)
34
Crowther MA, Levy G, Lu G et al. A phase 2 randomized, double-blind, placebocontrolled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Presented at the 56th annual meeting of the American Society of Hematology, San Francisco, December 6—9, 2014.
(check this in PDF content)
35
Crowther MA, Mathur V, Kitt M et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Presented at the 55th annual meeting of the American Society of Hematology, New Orleans, December 7—10, 2013.
(check this in PDF content)
36
Crowther MA, Kittl E, Lorenz T et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost, 2013, 11(Suppl 2): OC 20.1.
(check this in PDF content)
37
Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med, 2015, 373: 2413-2424.
(check this in PDF content)
38
Laulicht B, Bakhru S, Jiang X et al. Antidote for new oral anticoagulants: mechanism of action and binding speci_city of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June 29 — July 4, 2013. Abstract (http://www.eventure- online.com/eventure/publicAbstractView.do?id=226718&congress Id=6839).
(check this in PDF content)
39
Bakhru S, Laulicht B, Jiang X et al. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation, 128: A18809.
(check this in PDF content)
40
Bakhru S, Laulicht B, Jiang X et al. Reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circulation, 130: A19361.
(check this in PDF content)
41
Hollenbach S, Lu G, DeGuzman F et al. Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model — only andexanet reverses markers of fXa-mediated anticoagulation.Circulation, 2014, 130(Suppl 2): A14657.
(check this in PDF content)
42
G Lu, J Kotha, JM Cardenas et al. In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent. Circulation, 2014, 130: A18218.
(check this in PDF content)
43
Ansell JE, Bakhru S, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med, 2014, 339: 2141-2142.
(check this in PDF content)
44
Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI for the Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost,2016, 14: 623-627.
(check this in PDF content)
45
Sartori MT, Prandoni P. How to effectively manage the event of bleeding complications when using anticoagulants. Expert Rev Hematol,2016, 9(1): 37-50.
(check this in PDF content)
46
Abo-Salem E, Becker RC. Reversal of novel oral anticoagulants. Current Opinion in Pharmacology, 2016, 27: 86-91.
(check this in PDF content)